- Conditions
- Renal Impairment
- Interventions
- ESK-001
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 4
- States / cities
- Miami, Florida • Miami Lakes, Florida • Orlando, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pharmacokinetics
- Interventions
- ESK-001, Rabeprazole
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- SLE
- Interventions
- Envudeucitinib, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 48
- States / cities
- Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more
- Conditions
- Healthy Volunteer
- Interventions
- ESK-001, Moxifloxacin (400 mg), Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Plaque Psoriasis
- Interventions
- envudeucitinib
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 25 more
- Conditions
- Plaque Psoriasis
- Interventions
- Envudeucitinib, Apremilast, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 49 more
- Conditions
- Hepatic Impairment
- Interventions
- envudeucitinib
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Lake Forest, California • Miami Lakes, Florida • Orlando, Florida + 1 more
- Conditions
- Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis
- Interventions
- ESK-001
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Plaque Psoriasis
- Interventions
- ESK-001, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 33 more
- Conditions
- Safety and Tolerability
- Interventions
- Experimental drug: ESK-001, Placebo
- Drug · Other
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
- Interventions
- Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Pheonix, Arizona + 79 more
- Conditions
- Plaque Psoriasis
- Interventions
- Envudeucitinib, Placebo, Apremilast
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more